Imunon (IMNN) said Friday it received positive data showing improvement in overall and progression-free survival from a phase 2 study of IMNN-001, an investigational therapy for the treatment of advanced ovarian cancer.
Shares more than doubled as intraday trading volume catapulted to over 330.6 million from a daily average of about 532,000.
Merus (MRUS) shares soared 36% amid heavy trading after the company reported favorable interim cancer trial results overnight.
Over 5.63 million shares traded intraday versus a daily average of roughly 836,000.
Douglas Elliman (DOUG) has received a merger offer from Anywhere Real Estate (HOUS) this week that would value the company at roughly double its current share price, Bloomberg reported Friday, citing people with knowledge of the matter.
Shares soared 33%, with intraday trading volume at nearly 12 million compared with a daily average of roughly 543,000.
Price: 1.10, Change: +0.68, Percent Change: +164.74
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。